Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the COVID-19 pandemic, has posed severe threats to global public health, highlighting an urgent need to understand its pathogenesis and to develop antiviral therapies. Both DNA and RNA viruses can modulate cell cycle progression to maximize their replication.1 However, the effects of SARS-CoV-2 on cell cycle progression remains largely unknown.
Here, in our efforts to identify host factors associated with SARS-CoV-2 infection by proteome analysis (Supplemental Figs. S1 and S2), cell cycle-related proteins were found to be the most enriched proteins upon SARS-CoV-2 infection at both 12 and 24 h post-infection (hpi) (Supplemental Fig. S2c, d). In detail, expressions of the regulators of cell cycle, including cyclin-dependent kinase 1 (CDK1), CDK2, cyclin B1, and other cell cycle-related proteins, such as cell division cycle 20 (Cdc20), Wee1-like protein kinase (WEE1), Bub1, Bub3, and aurora kinase A (AURKA) were all increased at 12 hpi, while decreased at 24 hpi (Fig. 1a and Supplemental Fig. S3a–e). Immunoblots further confirmed the expression of cyclin B1, CDK1 and CDK2 upon SARS-CoV-2 infection (Fig. 1b and Supplemental Fig. S3f-i). Transcriptome analysis also showed an enrichment of cell cycle-related transcripts at 24 hpi (Supplemental Fig. S2e, f), and the profile of CDK2, cyclin B1, WEE1, and AURKA at the mRNA expression levels was consistent with the protein levels (Fig. 1a and Supplemental Fig. S3a, e). Overall, the integrative transcriptome and proteome analyses indicated that SARS-CoV-2 infection may interfere with host cell cycle progression.
Next, we determined if SARS-CoV-2 infection manipulates host cell cycle progression. Caco-2 cells infected with SARS-CoV-2 were analyzed for cell cycle distribution by flow cytometry, revealing that there were 26.1% of the mock-infected cells in the S phase, while 31.1%, 35.1%, and 48.5% of cells in the S phase after SARS-CoV-2 infection at the multiplicity of infection (MOI) of 0.01, 0.1 and 1.0, respectively, with a significant difference between the viral infection groups and control group (Fig. 1c). An obvious accumulation of cells in the G2/M phase was also observed in SARS-CoV-2-infected cells (19.5%, at the MOI of 1.0) as comparison with the mock-infected cells (10.3%) (Fig. 1c). Furthermore, Vero and HEK293T-hACE2 cells (293T cells expressing human angiotensin-converting enzyme 2) also displayed significantly higher cellular proportions of S and G2/M phases after SARS-CoV-2 infection (Supplemental Fig. S4a–d). The viral infection was shown to affect the S phase progression at early infection stage and to interfere with the G2/M phase progression at the late infection stage (Supplemental Fig. S4e, f). Taken together, these results indicated that SARS-CoV-2 manipulates the host cell cycle and causes cell cycle arrest at the S and G2/M phases.
Given that cells in different cell-cycle phases may affect the virus-mediated cell cycle arrest, we further synchronized cell populations to confirm the effect of SARS-CoV-2 infection on cell cycle progression. Caco-2 cells were synchronized to the G0/G1, S, and G2/M phases using serum starvation, thymidine, or nocodazole, respectively (Supplemental Fig. S5a, b). For the thymine-treated cells, the percentage of S and G2/M cells was 54.0% and 2.5% in the mock-infected group, while they were increased to 58.2% and 5.2% in the SARS-CoV-2 infection group, which was significantly higher than the mock infection group (Fig. 1d). SARS-CoV-2 infection of serum deprivation and nocodazole-treated cells also resulted in significantly higher proportions of S and G2/M phases (Supplemental Fig. S5c, d), confirming that SARS-CoV-2 infection can induce cell cycle arrest at the S and G2/M phases.
Viruses manipulate cell cycle progression to generate resources and cellular conditions beneficial for viral assembly and replication.2 We thus detected if synchronization of G2/M and S-phases can promote viral replication. After blocked at different phases, Caco-2 cells were infected with SARS-CoV-2. At 30 min post-infection, there was no obvious difference in viral replication between the control and synchronized cells (Fig. 1e). However, at 48 hpi, SARS-CoV-2 replicated significantly higher in the cells treated with thymine and nocodazole, while the viral replication was suppressed in the starvation group (Fig. 1f, g), indicating that synchronization of the G2/M- and S-phases does not affect viral adsorption, but promotes the replication of SARS-CoV-2.
We further investigated the effects of SARS-CoV-2 infection on cell cycle regulators of S/G2 phases, showing that the abundance of cyclin B1, CDK1 and CDK2 was increased before 24 hpi, but decreased at 48 hpi (Fig. 1b and Supplemental Fig. S3f–i). We also examined the nuclear translocation of cyclin B1 and CDK1, which is critical for cells to enter the mitotic phase.3 Immunofluorescence showed interrupted nuclear translocation of cylinB1 and CDK1, and nuclear fractionation analysis revealed reduced cyclin B1 and CDK1 in the nuclei after SARS-CoV-2 infection (Fig. 1h, i).
During cell cycle progression, cyclin B1 can be accumulated in the G2 phase, whose ubiquitination and degradation through anaphase-promoting complex (APC/C) is essential for cells to exit mitosis. APC/C can be manipulated by viruses to induce cells arrest at the G2/M phase.4 The activity of APC/C can be regulated by Cdc20 and the spindle assembly checkpoint (SAC).5 As seen in the proteomic profiling of SARS-CoV-2 infected cells, the expression of two SAC members (Bub1 and Bub3) and Cdc20 was elevated at 12 hpi, while decreased at 24 hpi (Supplemental Fig. S3b–d). Similarly, there were 21 increased APC/C substrates, whereas 4 decreased substrates upon SARS-CoV-2 infection at 12 hpi (Supplemental Fig. S6a and Table S1). Immunoblot confirmed that the expression levels of Bub1, Cdc20, and AURKA (substrate of APC/C) were elevated at 12 hpi, while decreased at 24 hpi, and displayed another elevation at 48 hpi (Fig. 1j, k, and Supplemental Fig. S6b, c), indicating that SARS-CoV-2 infection can suppress the activity of APC/C at 24 hpi.
To evaluate the contribution of SAC activation to SARS-CoV-2 replication, we tested the antiviral effect of the inhibitor, reversine, a pan inhibitor of aurora kinases, which can specifically inhibit the SAC. Reversine inhibited half-cell viability at the concentration of 2.25 μM (Supplemental Fig. S7), thus, 0.5 μM, 1.0 μM, and 2.0 μM of reversine was used to test its inhibitory effect on replication of SARS-CoV-2, showing that 0.5 μM reversine had an inhibitory rate of 93.8% for viral replication, 1.0 μM and 2.0 μM reversine had an inhibitory rate of 97.4% as comparison with DMSO-treated group (Fig. 1l).
Moreover, as the expression of AURKA was significantly increased upon SARS-CoV-2 infection at 48 hpi (Fig. 1k), we also employed two inhibitors of AURKA, AT9283 and MK5108, to test their inhibitory effects on SARS-CoV-2 replication, showing that 0.01 μM AT9283 had no significant effect on viral replication, 0.1 μM and 1 μM AT9283 had an inhibitory rate of 50.0–66.2% for viral replication, 10 μM and 100 μM AT9283 had an inhibitory rate of 90.1–99.7% as comparison with the control group, with the half maximal inhibitory concentration (IC50) value of 0.43 μM in Caco-2 cells (Fig. 1m); while 0.01 μM, 0.1 μM and 1 μM MK5108 showed no significant inhibitory effect on replication of SARS-CoV-2, 10 μM MK5108 had an inhibitory rate of 33.2%, and 100 μM MK5108 had an inhibitory rate of 99.1%, with the IC50 value of 4.02 μM (Fig. 1n). Consistently, immunofluorescence analysis showed that reversine and AT9283 significantly suppressed the replication of SARS-CoV-2 (Fig. 1o). These data indicated that inhibitors of SAC and AURKA can effectively suppress SARS-CoV-2 replication in vitro.
In summary, our findings reveal that SARS-CoV-2 manipulates cell cycle checkpoint and induces host cells arrest at the G2/M and S phases to facilitate viral replication, and inhibitors of SAC and AURKA can effectively inhibit viral replication, suggesting a potential antiviral target of host cell cycle checkpoint for COVID-19 (Extended Discussion).
The mass spectrometry data were uploaded to iProX (IPX0003647000) and the raw transcriptome data were uploaded to the NCBI Sequence Read Archive (PRJNA783650).
Bagga, S. & Bouchard, M. J. Cell cycle regulation during viral infection. Methods Mol. Biol. 1170, 165–227 (2014).
Zheng, C. & Tang, Y. D. The emerging roles of the CDK/cyclin complexes in antiviral innate immunity. J. Med. Virol. 94, 2384–2387 (2022).
Vermeulen, K., Van Bockstaele, D. R. & Berneman, Z. N. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif. 36, 131–149 (2003).
Fehr, A. R. & Yu, D. Control the host cell cycle: viral regulation of the anaphase-promoting complex. J. Virol. 87, 8818–8825 (2013).
Mo, M., Shahar, S., Fleming, S. B. & Mercer, A. A. How viruses affect the cell cycle through manipulation of the APC/C. Trends Microbiol. 20, 440–448 (2012).
This work was supported by grant from the National Natural Science Foundation of China (81972873, 82002165, 81871699, and 82072330), the Biosafety Research Special Plan of the Logistics Support Department of the Military Commission (923070201202), the young and middle-aged science and technology innovation leaders and teams of the Jilin Provincial Department of Science and Technology (20200301001RQ), China Ministry of Science and Technology Key Research and Development Program (2022YFF1203204), Jilin Province Pathogen and Infection Informatics International Joint Research Center (20210504004GH), the Pearl River Talent Plan in Guangdong Province of China (2019CX01N111), the Scientific and Technological Research Projects of Guangzhou, China (202103000008), and the Medical Innovation Team Project of Jilin University (2022JBGS02).
The authors declare no competing interests.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Sui, L., Li, L., Zhao, Y. et al. Host cell cycle checkpoint as antiviral target for SARS-CoV-2 revealed by integrative transcriptome and proteome analyses. Sig Transduct Target Ther 8, 21 (2023). https://doi.org/10.1038/s41392-022-01296-1